EUROPEAN PLASMA RESEARCH ACCELERATOR WITH EXCELLENCE IN APPLICATIONS

#### The EuPRAXIA Project: Status and Perspectives

Ralph Assmann (DESY & INFN) EuPRAXIA@SPARC\_LAB TDR I Review Committee, Frascati (Virtual)

22.02.2021









This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 653782.



# **The EuPRAXIA Project**



- First ever international design of a **plasma accelerator facility**.
- Challenges addressed by EuPRAXIA since 2015:
  - How can plasma accelerators produce usable electron beams?
  - For what can we use those beams while we increase the beam energy towards HEP and collider usages?
- **CDR for a distributed research infrastructure** funded by EU Horizon2020 program. Completed by 16+25 institutes.
- Next phase consortium with 40 partners + 10 observers.
- Applied to ESFRI roadmap update 2021 with government support in Sep 2020.
- Judged as eligible and has entered the ESFRI review.



600+ page CDR, 240 scientists contributed





EuPRAXIA provides **particle and photon beams with exceptionally short duration and small size** – ideal for the study of complex systems and ultrafast processes:

•	Biology	structural biology, research on understanding molecular structures and biochemical processes	
•	Chemistry	crystallography, research on understanding molecular structures and chemical processes	
•	Medicine	pharmacological developments, research on understanding underlying mechanisms of drug	
		operating modes and delivery, diseases, etc.	
•	Material science	crystallography, research on understanding molecular structures and processes, e-beam	
		machining, material analysis	
•	Physics	crystallography, research on understanding structures and processes	
•	Archaeology & history	non-destructive testing, material analysis	

Beyond those applications various **use cases of co-development** including **accelerator R&D**, **photon science** technologies, **compact and industrial** applications, plasma-based acceleration and secondary sources for **high-energy physics**.

# **EuPRAXIA Deliverables and User Interests**



EuPRAXIA is designed to deliver at 10-100 Hz ultrashort pulses of

- Electrons (0.1-5 GeV, 30 pC)
- Positrons (0.5-10 MeV, 10<sup>6</sup>)
- Positrons (GeV source)

**E**<sup>u</sup>PRAXIA

- Lasers (100 J, 50 fs, 10-100 Hz)
- Betatron X rays (5-18 keV, 10<sup>10</sup>)
- FEL light (0.2-36 nm, 10<sup>9</sup>-10<sup>13</sup>)

Expressions of interest from **95 research groups** representing several thousand scientists in total.







#### IMPORTANT: EuPRAXIA design includes RF injectors, transfer lines, undulator lines, shielding, ...

PRA AIA

Realistic intermediate goals at established labs:

- 150 MeV  $\rightarrow$  1 GeV  $\rightarrow$  5 GeV (FEL + other applications)
- 1 plasma stage  $\rightarrow$  2 plasma stages  $\rightarrow$  multiple

EMERGENCY

- factor 3 facility size reduction  $\rightarrow$  factor 10  $\rightarrow$  ...
- Low charge, 10 Hz apps of e- (+ positron generation)
   → high charge, 10 Hz applications (FEL) → 100 Hz



### Some of EuPRAXIA's Ideas and Innovation







### **New Consortium Agreement Signed in Dec 2020**

Horizon 2020



#### 40 Member institutions in:

- Italy (INFN, CNR, Elettra, ENEA, Sapienza Università di Roma, Università degli Studi di Roma "Tor Vergata")
- France (CEA, SOLEIL, CNRS)
- Switzerland (EMPA, Ecole Polytechnique Fédérale de Lausanne)
- Germany (DESY, Ferdinand-Braun-Institut, Fraunhofer Institute for Laser Technology, Forschungszentrum Jülich, HZDR, KIT, LMU München)
- United Kingdom (Imperial College London, Queen's University of Belfast, STFC, University of Liverpool, University of Manchester, University of Oxford, University of Strathclyde, University of York)
- Poland (Institute of Plasma Physics and Laser Microfusion, Lodz University of Technology, Military University of Technology, NCBJ, Warsaw University of Technology)
- Portugal (IST)
- Hungary (Wigner Research Centre for Physics)
- Sweden (Lund University)
- Israel (Hebrew University of Jerusalem)
- Russia (Institute of Applied Physics, Joint Institute for High Temperatures)
- United States (UCLA)
- CERN
- ELI Beamlines



#### **New Consortium Agreement Signed in Dec 2020**

(10 observer institutes)







# **ESFRI Proposal Submitted in Sep 2020**



- EuPRAXIA strongly supported in European research landscape, it is timely, it offers highly attractive opportunities for innovation with industry, novel applications and pilot users.
- Lead Country: Italy (LNF/INFN)
   Political and financial support letter sent to
   ESFRI by Italian Ministry
- **Political support letters** (at least two needed from countries):
  - Hungary
  - Portugal
  - Czech Republic (ELI beamlines)
  - UK
- Note: All operational costs covered by host countries.



From political + scientific landscape it is seen that **both Czech Republic and UK would be excellent sites for the second leg of EuPRAXIA**, connecting to existing facilities with laser expertise, users and few 100 million € preinvest.





#### **Government Support Letters**





#### plus 32 non-governmental support letters

EuPRAXIA - R. Assmann, LNF, 02/2021





We are glad to inform you that, following ESFRI internal procedures, **the proposal "European Plasma Research Accelerator with Excellence in Applications - EuPRAXIA" has been considered eligible** and can now be assessed for entering the ESFRI Roadmap 2021.

The evaluation exercise has just started and below you can find the next steps with an indicative timeframe:

- Invitation for the hearing with list of critical questions: February-March 2021
- Hearing: April-May 2021



#### **Budget Overview and Cost-Benefit Analysis**

#### (all prepared according to ESFRI and EU rules)



Project duration	10 years	
	10 years	
Full cost (including manpower, past CDR cost and termination cost)	569 M€	
Cost of Phase I (including manpower and past CDR cost)	388 M€	
Operational cost	30 M€/y	
Internal rate of return	9.22 %	
Start of pilot operation	2028	
Funding secured (status 11/2020)	<b>118 M€</b> (21 % of full cost)	
OP budget secured (status 11/2020)	9 M€/y <i>(30 %)</i>	

Return rate found in cost-benefit analysis shows the expected gain of the sustained EuPRAXIA investment also in economical terms. Credits to our consultant F. Brottrier.



6.5 Socio-economic analysis	
Net Present Value (ENPV)	80 985 945
Internal Rate of Return (ERR)	9.22%
Benefit-Cost ratio (B/C)	1.10

The chart below indicates the variations of the ENPV when changing the socio-discount rate between 0 and 20%. As per the definition of internal rate of return, EuPRAXIA's socio-economic net present value becomes negative when the socio-economic discount rate exceeds 9.22%.



# **EuPRAXIA Schedule**







#### European World-Class RI on compact

**accelerators** for the end of the 2020's to the beginning of the 2060's More detail in Master Schedule





Horizon 2020

Features to be added with decision on second site or in later phases are indicated in lighter shades



### **The Laser-Driven EuPRAXIA Construction Site**

(decide in 2023, candidates alphabetic: CNR, ELI-Beamlines, EPAC, LNF)







#### The Beam-Driven EuPRAXIA Construction Site (EuPRAXIA@SPARC\_lab)



EuPRAXIA combines **compact X band RF technology** from CLIC and the plasma accelerator **at its Frascati construction site**! Brings confidence and **excellent synergy** with international linear collider efforts!

55 m

6 m 1 Klystrons and modulators

Injector and linac



Plasma



The executive design of the building has officially started few weeks ago, the delivery of the design is expected in November 2020.

Multiple users from different fields: studying and understanding bacteria, viruses, materials, ... using intense bursts of photons, electrons, positrons resolving timedependent processes in ultra-fast science co-developing novel technologies for accelerators, users, ...



#### **Cost Split Preparation and Implementation**

(from ESFRI, excluding manpower cost)



Cost Breakdown for Preparation & Implementation	Investment cost (excl. contingencies, payroll)	
Laser-driven plasma acceleration site	148 M€	
Beam-driven plasma acceleration site	141 M€	
Excellence Centres	41.5 M€	
Laser prototyping (Clusters)	38.5 M€	
Plasma prototyping (Clusters)	7.3 M€	
Applications prototyping (Clusters)	25.7 M€	
Other prototyping (Clusters)	26.7 M€	
Central EU Project Office	0.8 M€	
Total	429.5 M€	

The full EuPRAXIA CDR includes, amongst others,

- about 12 M€ of prototyping cost for Frascati applications (done by partners)
- about **4 M€** of of prototyping for Frascati plasma structure (done by partners)
- about 40 M€ of additional component costs to be installed at Frascati (not in EuPRAXIA@SPARClab budget)
- profits from laser and other prototyping work, excellence centres, ...

Only the full EuPRAXIA project realizes significant synergy benefits of a fully European project!



#### **European Interests and Possible Contributions**

(final decisions depend on funding and TDR solutions)





# A Excellence Center for Laser Acceleration and FEL



3 French institutions have signed the EuPRAXIA Consortium Agreement : CNRS, CEA and Soleil

cnrs

French contribution is structured around 2 main facilities and projects



- high repetition rate (≥100Hz) LPA sources development
- **FEL** LPA-driven development, robust high quality beam LPA development (SOLEIL/LOA)



10 Hz, 150 MeV laser-plasma injector (LPI) test facility devoted to:

- advanced online control of LPI
- plasma target development for high beam beam quality
- beam transport for staging
   Phase 1 funded as French national
   contribution to EuPRAXIA

#### In addition the following CNRS labs contribute to **EuPRAXIA clusters**



: multi-PW driver LPA experimental demonstration at APOLLON, applications to HEP and other field, beam diagnostics and compact beam transport, and theory simulations and continuous development of PI(Smile:)



: **new advanced laser technology development** : Compressor, intensity stabilization, focal spot alignment stabilization, amplification stage, beam transport + bring benefit from its close links with the laser industrials partners to ensure the economic feasibility.



: R&D of optimised LPI in tailored plasma density profile and of specific plasma components, based on novel discharge schemes or laser ionised plasmas, suitable for laser guiding over large propagation distances and experimental tests









#### **Participations to EuPRAXIA:**





UH1100 versatile and user friendly environment for Laser Plasma Acceleration studies at LIDYL (CEA-CBRS, Université Paris Saclay (Image: Ph.Stroppa/CEA)



### **EuPRAXIA Laser-Driven Site Option CNR**



#### Preparation of the EuPRAXIA laser-driven site option at the CNR Campus in Pisa



- Builds on experience running the <u>existing facility</u> including a >200 TW laser driver for electron and proton beamlines currently active;
- Part of the National roadmap for Extreme Light Infrastructure, and founding participant to ELI along with INFN and Elettra ST;
- Currently engaging R&D on key EuPRAXIA pillars:
  - High average power laser development as efficient and reliable drivers
  - Validation of novel schemes for FEL quality laser-driven acceleration
  - Multi-disciplinary **user operation** at beamlines
- Currently promoting EuPRAXIA laser-driven site option at National and Regional levels;
- Strong focus or bio-medical uses of laser-driven sources or pre-clinical and clinical studies are motivating growing collaborations.
- ESFRI listing of EuPRAXIA will boost all related developments and innovation.



### **ELI-Beamlines**

e

beamlines



**ELI Beamlines master scheme** 



The Science Case



E1 Apps in molecular, biomedical L1 100 mJ / <20 fs / 1 kH & material sciences Pump thin disk Compressor ps OPCPA Yb:YAG preamps Master oscillator E2 Ti:sapphire 80 MHz, <6fs Common front end XUV / X-ray L2 generation Pump DPSSL multislab 'ml OPCPA preamps \* pulse cleaning 20 J / <15 fs / 10 Hz OPCPA Stage 2 chain RF clock E3 Er:fiber clock 2 J / <15 fs / 10 Hz Plasma physics ¥ 5 J lab astrophysics OPCPA Stage 1 chain Master timing switchya E4 L3 Pulse High-field "exotic" physics Pump DPSSL multislab Nd:glass 30 J / 20 fs / 10 Hz 1J / 20 fs / 10 Hz Ti:sapph front end E5 Electron acceleration 1.8 kJ / 0.5-5 ns L4 10 PW / 150 fs Nd:glass CPA chain E6 1 PW / 150 fs Proton 150 J / 0.5-5 ns acceleration

eti Jeamlines

#### Lasers and experiments



EuPRAXIA - R. Assmann, LNF, 02/2021



#### ELI-Beamlines: Compact X-FEL Development



From incoherent to coherent undulator X-ray source for users



Current RESEARCH PROGRAM Undulator photon radiation at ELI beamlines



Under preparation in E5 experimental hall 'First L3-laser light' in E5-LUIS → March 2021



'Swiss-FEL' type of undulator

EuPRAXIA - R. Assmann, LNF, 02/2021

# Plasma theory and simulations excellence center



• Long tradition in developing plasma simulation



• Instituto Superior Técnico (IST) is the largest science&engineering school in Portugal



- Concept collaboratorium
  - Platform for coordination, collaboration, scientific and technical exchange.
  - Lead coordination efforts for code development and integration
  - Front end for the EU exascale initiatives in plasma accelerators
  - Hub for new and disruptive ideas, to explore future directions of facility.
- Main goals
  - Simulation and theory support for EuPRAXIA teams involved in computing
  - Coordinate virtual interactions in EuPRAXIA in theory and simulations
  - Visiting/workshop program on plasma accelerators (advanced trainning, convene PhD students, Post-Docs and senior researchers.



# UK contributions to EuPRAXIA



#### Primary contribution through Excellence Centre (in CDR)

- Prototyping & Delivery of Application Beamlines (Betatron, high-& low-energy positrons, Gamma, Compton..): 91,570 k€
- Individual contributions from institutions to different clusters
- Coordinated by UK's Plasma Wakefield Accelerator Steering Committee (PWASC)

#### Potential Additional Contributions from the UK (through additional funding)

- Part 1: A LWFA-based user facility in EPAC for applications in 2024
- Part 2: A EuPRAXIA-driven technology development programme towards plasma-based X-FEL-ready beams
   High-rep rate (>100Hz), high-brightness, high-quality beams for plasma-based X-FELs

Slide from R. Pattahil et al









A potential flagship international research facility for propelling laser-driven plasma accelerators to transformative real-world applications

A distributed Infrastructure Proposal to combine EPAC with EuPRAXIA, for establishing the laser-driven arm of EuPRAXIA in the UK

First phase: developing EuPRAXIA-beamlines in collaboration with Universities and Accelerator institutes: £59M

Develop a 100Hz laser driver (technology development program exists already)

In the second phase (post-2024), expand the EPAC building to house the additional beamlines for EuPRAXIA

Infrastructure proposal submitted to UKRI



Science and Technology Facilities Council

Slide from R. Pattahil et al





- EPAC's spec (PW@10Hz) is very close to EuPRAXIA baseline (PW@20Hz)
- A dedicated facility for LWFA applications hitting several EuPRAXIA milestones
- EPAC will be operational in 2024 during EuPRAXIA construction period
- With EU funding, this could be a de-risking option for EuPRAXIA: technological & facility operations

Slide from R. Pattahil et al



#### Excellence Centre for Plasma Accelerators and High Repetition Rate Developments at DESY



- Plasma accelerators at DESY are progressing toward high beam quality, high average power, and applications
- Ongoing technology R&D will be important for integration at EuPRAXIA
- Key DESY facilities involved
  - FLASHForward >>: 10 kW, 1.2 GeV FEL-quality electron drive beam, user-facility-grade feedbacks, and advanced diagnostics
  - KALDERA: kHz, kW drive laser and laser-plasma accelerator, accelerator-grade control-system integration, and stability systems
- Research targeted at beam-quality conservation, high efficiency, high avg. power, stability, intelligent controls, and applicability
- 10-year development roadmap in place



Wakefield Sampling S.Schröder *et al.*, accepted, Nat. Commun. (2020)

**24-hour Operation** A.R.Maier *et al.,* Phys. Rev. X 10, 031039 (2020)



For further information, please contact jens.osterhoff@desy.de

# Hungarian user's interests



#### **Institute of Physics:**

The group has leading role in the high-field THz generation by optical rectification. Near single cycle THz pulses with well controlled waveform can be generated at the 0.3-0.7 THz frequency range. The pulses have excellent focusability and around 0.5 MV/cm field strength is available. Using the setups newly proposed by the group, even higher ~10 MV/cm electric field will be available in the near future. These pulses could be used for streaking and other dynamic manipulation of electrons. The group owns US patents for manipulating charged particles with terahertz radiation. J. Hebling et al., Opt. Express 10(21), 1161–1166 (2002), L. Pálfalvi et al., Opt. Express 25(24), 29560–29573 (2017), Gy. Tóth et al., Opt. Express 27(21), 30681-30691 (2019)

#### Interest: Carrier-envelope-phase (CEP) stable attosecond pulse generation:

Generation of extreme ultraviolet pulses with attosecond duration is nowadays routinely possible by high-order harmonic generation. However, a precise waveform control is difficult with this technique. Therefore, we proposed a device for producing CEP controlled singlecycle attosecond pulses in the EUV–VUV spectral range, which utilizes a LINAC or laser-plasma-based electron accelerator (the optimum electron energy is 1-2 GeV), a modulator undulator, and a radiator undulator. The waveform of the attosecond pulses can be engineered by the choice of the magnetic field distribution in the radiator undulator. Generation of both linearly and circularly polarized single-cycle attosecond pulses with up to 60 nJ energy and 90–400 attosecond duration in the 30–120 nm wavelength range are predicted by numerical simulation. We would like to perform proof-of-principle experiment in the EuPraxia project.

Z. Tibai et al., Phys. Rev. Lett. **113**, 104801 (2014) (basic consideration) Z. Tibai et al., Frontiers in Phys., 6, 140, (2018) (detailed numerical investigation) Gy Tóth et al., JOSA B, 35(5), A103 (2018) (extension of the technique for producing circularly polarized pulses) Z. Tibai et al., Applied Physics B, **124**, 113 (2018) (laser plasma accelerator based electron source)



UNIVERSITY OF SZEGED FACULTY OF MEDICINE DEPARTMENT OF ONCOTHERAPY

Virtus

#### University of Szeged, Department of Oncotherapy:

The department has gained expertise in cancer treatment based on different types of radiation therapies, including novel approaches under clinical evaluations, e.g. hadron therapy, mixed energy radiotherapy or immuno-radiotherapy. It is also committed in testing and developing novel approaches under preclinical evaluations, like FLASH-Radiotherapy (FLASH-RT), Microbeam Radiation Therapy (MRT) for example, shows promising results in minimizing the side effects of radiotherapy, i. e. it lets the applied dose to be increased drastically without the patient having post-treatment complications. A 17 Gy conventional irradiation induced pulmonary fibrosis in 100% of the animals 24-36 weeks post-treatment, whereas no animal developed complications below 23 Gy flash RT. The FAST-01 (FeAsibility Study of FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases) clinical study was launched 12. Oct 2020.

Synchrotron-based MRT composed of spatially fractionated, planar x-ray (50-600keV) 25-75 micron-wide beams, with a very sharp penumbra, separated by a distance several times of their beam width. These microbeams create unique dose profiles of alternating peaks and valleys with high peak-to-valley-dose-ratios (PVDR). They can be produced in highly brilliant synchrotron sources and are characterised with very small beam divergence and extremely high dose rate, >100 Gy/s.

Favaudon V, Fouillade C, Vozenin MC **Ultrahigh dose-rate, "flash" irradiation minimizes the side-effects of radiotherapy]** Cancer Radiother. 2015 Oct;19(6-7):526-31 M.-C. Vozenin, P. De Fornel, K. Petersson, V. Favaudon, et al **The advantage of FLASH radiotherapy confirmed in mini-pig and cat-cancer patients** Clin Cancer Res 2018 Bourhis J, Sozzi WJ, Jorge PG, Gaide O, Bailat C, Duclos F, et al. Treatment of a first patient with FLASH-radiotherapy. Radiother Oncol 2019; 139: 18–22. Zhang et al. Expert Rev Anticancer Ther. 2015 December

#### Interests:

Laser driven VHEE (Very High Energy Electron beams) can produce compton and betatron photons that are feasible for MRT. Ultraintense beam and ultrashort dose delivery results in short treatment time, and in general, in a treatment without increased entrance (skin) dose. There is no need for internal organ motion management. Since the EuPRAXIA electron beams make accessible high temporal and spatial resolution, the instrument would be ideal to perform immuno-RT, FLASH-RT and MRT treatments. In vivo an in vitro proof-of-principle experiments in MRT therapy.





Update had input from the European Network for Novel Accelerators (EuroNNAc), EuPRAXIA, ALEGRO, AWAKE, ... on novel accelerators.

b) Innovative accelerator technology underpins the physics reach of high-energy and high-inter It is also a powerful driver for many accelerator-based fields of science and industry. The technology consideration include high-field magnets, high-temperature superconductors plasma wakefield acceleration and other high-gradient accelerating structures bright muon beams, energy recovery linacs. *The European particle physics community must intensify accelerator R&D and sustain it with adequate resources. A roadmap should prioritise the technology, taking into account synergies with international partners and other communities such as photon and neutron sources, fusion energy and industry Deliverables for this decade should be defined in a timely fashion and coordinated among CERN and national laboratories and institutes.* 

> Success for our community, including EuPRAXIA → An expert panel has been formed for proposing an HEP-oriented R&D roadmap for plasma accelerators (chairs: R. Assmann & E. Gschwendtner)



### In Discussion: Structure EuPRAXIA HQ at LNF/INFN

to be set up in 2021 – fully operational in mid-2022 for PP EU Project



Local EuPRAXIA@SPARClab	EuPRAXIA HQ	Tasks
	Coordinator: R. Assmann	Project coordination + management
PL: Massimo Ferrario	Co-Coord: Massimo Ferrario	Represent local LNF/INFN pillar
TC: Antonio Falone 	<b>TC</b> : Antonio Falone	Planning
See organization chart by Massimo and Antonio	HQ Office Manager: G. Vinicola	• <u>eurpraxia-admin@infn.it</u> , calendar, events, contact point, coordinate technical EU reporting, central documentation
	Financial Officer: xxx	Financial planning, coordinate financial EU reporting, EU funding programs
	Outreach/PR Officer: xxx	<ul> <li>Communications, web page, newsletter, publications followup, local outreach (also politics, embassies)</li> </ul>
	Implementation Officer: xxx	Governance model EuPRAXIA RI
Structure and all names 🛁	Lead Science Officer: xxx	EuPRAXIA science and user outreach
tentative. Need to be agreed and approved at LNF and	HQ scientists: xxx, xxx	Work on EuPRAXIA solutions with WP's
EuPRAXIA collaboration board.	$\downarrow \rightarrow 10+10$ in	stitute consortium governing hoard steering committe

40+10 institute consortium, governing board, steering committe →



### Conclusion



- Collaboration of **41 institutes** produced a conceptual design report, now also published as peer-reviewed book in **EPJ**.
- EuPRAXIA is a **unique chance for Europe** in new technology.
- During course of project > 200 M€ funding approved in national projects of EuPRAXIA partners.
- New consortium agreement with 50 institutes signed.
   EuPRAXIA headquarters moved to Frascati.
- **ESFRI proposal** submitted and found eligible! Now in review.
- Next: 2021 decision for ESFRI, preparatory phase project, decision laser-driven site in 2023, TDR in 2025. In parallel: Legal and financial model.



600+ page CDR, 240 scientists contributed



# **Some Quotes from Support Letters**

(from 32 non-governmental support letters)



"...a fantastic opportunity for the **regional scientific development** as it would provide state-of-the-art facilities for education and training of the **young community**..." (TIARA)

"...is timely and has an extremely high potential for strengthening the European position in a world-wide highly competitive landscape." (Thales) "...truly European project that realizes a major competitive advantage, strong scientific impact, and important societal benefits." (LEAPS)

"...tackles the need for compact and costeffective particle and radiation sources for research and industry, as not yet addressed elsewhere at a European level." (AVS)

Many thanks to all our supporters from local government, interest organizations, industry, universities and research organizations! This is extremely encouraging and valuable support!

It supports our view that there can be a very strong societal impact of such a European infrastructure on compact plasma accelerators!

# Thank you

Many thanks to I. Barna, P. Campana, K. Cassou, B. Cros, A. Falone, A. Ferran Pousa, M. Ferrario, L. Gizzi, A.Molodozhentsev, P. Nghie, J. Osterhoff, R. Pattahil, A. Specka, J. Viera for help with the preparation of this talk, provision of slides and material..

Many apologies to my colleagues and the many outstanding results, contributions and infrastructures I could not mention today!

Many thanks to our consortium members and involved management for their untiring support to EuPRAXIA and help to form the new consortium!

Special thanks to P. Campana, A. Zoccoli, L. Silva, J. Viera, G. Korn, R. Hvezda, P. Levai, R. Pattahil, M. Thomson for help on obtaining the governmental support letters .

Special thanks to Maria Weikum, Massimo Ferrario, Pierluigi Campana, Antonio Falone and Franck Brottier for the ESFRI roadmap application support.